Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Before saying yes to the medical test, know the risks and benefits
United Kingdom
-
Blood marker may flag Alzheimer's-related changes in Down syndrome decades before symptoms appear
United Kingdom
-
We may need a new map to properly interpret our genome
United Kingdom
-
Optogenetic therapy shows early signs of improving vision in inherited blindness
United Kingdom
-
Heart recovery technique adapted for pediatric transplants
United Kingdom
-
Flu season may be starting early; experts say get vaccinated now
United Kingdom
-
Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer
United Kingdom
-
First single-cell DNA analysis reveals mitochondrial damage in vulnerable Parkinson's brainstem neurons
United Kingdom